Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 108

    1.

    Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis.

    de Pont AC, Schultz MJ.

    Crit Care. 2009;13(1):113. Epub 2009 Feb 2. Review.

    PMID:
    19226446
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.

    Camporota L, Corno E, Menaldo E, Smith J, Lei K, Beale R, Wyncoll D.

    Crit Care. 2008;12(6):R163. Epub 2008 Dec 18.

    PMID:
    19094233
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17084715
    [PubMed - indexed for MEDLINE]
    4.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17431957
    [PubMed - indexed for MEDLINE]
    5.

    The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.

    Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R.

    Crit Care. 2009;13(3):R103. Epub 2009 Jun 30.

    PMID:
    19566927
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

    De Backer D.

    Drug Saf. 2007;30(11):995-1010. Review.

    PMID:
    17973539
    [PubMed - indexed for MEDLINE]
    7.

    Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

    Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

    Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.

    PMID:
    18394162
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.

    PMID:
    15640631
    [PubMed - indexed for MEDLINE]
    9.

    Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

    [No authors listed]

    Prescrire Int. 2007 Feb;16(87):7-9.

    PMID:
    17323514
    [PubMed - indexed for MEDLINE]
    10.

    Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

    Hodder RV, Hall R, Russell JA, Fisher HN, Lee B.

    Crit Care. 2009;13(3):R78. Epub 2009 May 20.

    PMID:
    19457240
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

    Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.

    Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.

    PMID:
    17556722
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.

    Vincent JL, Laterre PF, Decruyenaere J, Spapen H, Raemaekers J, Damas F, Rogiers P, Sartral M, Haentjens T, Nelson D, Janes J.

    Acta Clin Belg. 2008 Jan-Feb;63(1):25-30.

    PMID:
    18386762
    [PubMed - indexed for MEDLINE]
    13.

    Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

    Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP.

    Pediatrics. 2004 Jan;113(1 Pt 1):7-17.

    PMID:
    14702440
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

    Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2003 Jan;31(1):12-9.

    PMID:
    12544987
    [PubMed - indexed for MEDLINE]
    15.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.

    PMID:
    18158435
    [PubMed - indexed for MEDLINE]
    16.

    Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

    Barie PS, Hydo LJ, Shou J, Eachempati SR.

    Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

    PMID:
    16895513
    [PubMed - indexed for MEDLINE]
    17.

    Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.

    Levy M, Levi M, Williams MD, Antonelli M, Wang D, Mignini MA.

    Intensive Care Med. 2009 Jul;35(7):1196-203. Epub 2009 Apr 15. Erratum in: Intensive Care Med. 2009 Jul;35(7):1322-3.

    PMID:
    19367397
    [PubMed - indexed for MEDLINE]
    18.

    Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

    Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

    Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.

    PMID:
    15774234
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.

    Yan SB, Nelson DR.

    Crit Care Med. 2004 May;32(5 Suppl):S239-46.

    PMID:
    15118525
    [PubMed - indexed for MEDLINE]
    20.

    New and emerging therapies for sepsis.

    Healy DP.

    Ann Pharmacother. 2002 Apr;36(4):648-54. Review.

    PMID:
    11918516
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk